The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ANNX | -58.45% | -87.52% | -34.03% | -83% |
| S&P | +16.23% | +94.45% | +14.22% | +110% |
Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington’s and alzheimer’s disease, multiple sclerosis, glaucoma, parkinson’s disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.91M | -6.5% |
| Market Cap | $263.31M | -49.0% |
| Market Cap / Employee | $2.56M | 0.0% |
| Employees | 103 | 0.0% |
| Net Income | -$49.16M | -66.0% |
| EBITDA | -$50.81M | -55.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $132.29M | -15.9% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $24.91M | -10.6% |
| Short Term Debt | $2.72M | 15.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -55.74% | -19.7% |
| Return On Invested Capital | -42.56% | 8.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$38.09M | -75.4% |
| Operating Free Cash Flow | -$38.07M | -75.4% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.73 | 1.64 | 0.72 | 1.08 | -36.07% |
| Price to Tangible Book Value | 1.73 | 1.64 | 0.72 | 1.08 | -36.07% |
| Enterprise Value to EBITDA | -13.43 | -9.21 | -0.89 | -3.08 | -66.29% |
| Return on Equity | -48.1% | -50.8% | -66.1% | -66.7% | 58.18% |
| Total Debt | $29.61M | $28.97M | $28.31M | $27.63M | -8.52% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
